Articles mentioning Bristol-Myers Squibb Co. (BMY)

Results 11 - 20 of 764 : Previous 1 2 3 4 5 6 7 8 9 Next

Get RSS Feed for BMY

Investing | February 14, 2015

Game-Changing News: Researchers May Have Discovered the Cause of Intestinal Cancer

Did researchers really uncover the mechanism behind intestinal cancer formation? Find out what game-changing news this latest study brings to light and how this could help drug developers plan their attack against intestinal cancers.

Investing | February 07, 2015

3 Drugs That Could Become Blockbusters in 2015

Pharmacyclics, Celgene Corp., Bristol-Myers Squibb, and Pfizer could see sales of new drugs eclipse $1 billion this year.

Investing | February 07, 2015

3 Blockbuster Drugs That May Be Obsolete in 5 Years

Motley Fool experts highlight three blockbuster-selling therapies that could fall by the wayside in the next five years.

Investing | February 04, 2015

5 Things Bristol-Myers Squibb Co.'s Management Wants You to Know

Bristol-Myers Squibb this week held a conference call to discuss its fourth-quarter and full-year results. Here are five things management wants investors to know.

Investing | January 27, 2015

Bristol-Myers Squibb Co.'s Fourth Quarter Earnings Warn of a Tough Year Ahead

Bristol-Myers Squibb Co. reported its fourth quarter earnings Tuesday morning. Here's what investors need to know.

Investing | January 12, 2015

Bristol-Myers Squibb's New Cancer Drug Hits the Mark: What's Next?

Bristol-Myers Squibb announced that its closely-watched cancer drug, Opdivo, achieved a significant clinical milestone. Here's what you need to know.

Investing | January 10, 2015

Can You Guess the Most Common Reason People Visit the Doctor?

The most common reason people visit their doctor, according to a study from the Mayo Clinic, may surprise you.

Investing | December 24, 2014

This Cancer Drug War Is Just Getting Started

The FDA approves Bristol-Myers Squibb's Opdivo, pitting it against Merck's Keytruda that was approved earlier this year.

Investing | December 19, 2014

3 Pharma Giants Growing Significantly Faster Than Pfizer, Inc.

Pfizer is a staple in most retirement and income portfolios, but investors can find stronger growth prospects in each of these three big pharmaceutical stocks.

Investing | December 06, 2014

Is Obamacare Failing Where It's Needed Most?

A recent study shows that while Obamacare has dramatically reduced the number of uninsured, it's failing to provide a boost in this important area which is vital to Obamacare's long-term success.

Results 11 - 20 of 764 : Previous 1 2 3 4 5 6 7 8 9 Next

Get RSS Feed for BMY


Advertisement